Xencor Inc. (XNCR)
Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Xencor: Vudalimab Development Along With Hidden Gem Candidate
Monotherapy and combination dose cohort data from the phase 2 study, using vudalimab for the treatment of patients with mCRPC, expected 1st half of 2025. The global metastatic castrate-resistant prostate cancer treatment market size is projected to reach $20.70 billion by 2031. XmAb942 is a candidate in the company's pipeline which has the potential to become the best in class anti-TL1A inhibitor for the treatment of autoimmune disorders like UC and CD.
Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xencor Stock Gains 23% on Encouraging Pipeline Advancements
XNCR moves four new XmAb drug development programs for autoimmune diseases. It also provided favorable updates for two of its oncology drug candidates.
Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.37 per share a year ago.
